Life Sciences Voice’s Post

Despite ambitious goals, Pear Therapeutics faced go-to-market challenges and revenue difficulties. Now, nearly one year following Pear’s bankruptcy, the company’s assets have been acquired by four prominent players in the industry. What does this mean for DTx? Let's discuss! Join the waitlist for an insightful discussion on: 🔍 Broader implications for the digital health industry. 🚀 Confidence in digital therapeutics technology and future market shaping. 💡 Revenue generation strategies with innovative product lines. Meeting Full. JOIN THE WAITLIST NOW ➡️ https://lnkd.in/g-ujacYw #digitalhealth #digitaltherapeutics #healthtech

We’re delighted to share insights from our CEO, Dr. Ross Burn, on our latest acquisition of Reach Separations: "We are excited to welcome Reach Separations into the CatSci Ltd Group. The need for solving complex analytical problems while meeting the ever-evolving regulatory demands is growing alongside the development of new modalities, such as oligonucleotides, TACs, and glues. Joining forces with Reach gives our customers access to end-to-end coverage of the analytical development lifecycle, taking them from discovery through to GMP manufacture, and ultimately enabling them to help patients in need." This acquisition enhances our ability to deliver end-to-end analytical support from discovery through launch. Together with Reach, we are committed to better serving our customers and accelerating the development of life-changing therapeutics. Discover more here: https://lnkd.in/ebprErGt #ExcellenceInMedicinesDevelopment #ProudToBeCatSci #DrugDevelopment #MedicinesDevelopment

🦃 Thanksgiving Fun Fact with a Clinical Trials Twist! As we gear up for the Thanksgiving celebrations in the US, here's a quirky fact you might not know: The first Thanksgiving feast in 1621 lasted three whole days! 🍁 Now, that's what we call a long-term commitment - something we in the clinical trials' industry know quite a bit about! In the world of clinical trials, long-term commitment is key. From the early stages of research to the final phases of drug development, it's our sustained dedication that leads to groundbreaking medical advancements! . . . #clinicalresearch #biopharma #drugdevelopment #drugresearch #cro #clinicaltrials #Thankful #Thanksgiving

Thoughts on this? >> New directions in a post IO apocalypse >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #biotech #competitivemarketing #healthcare #pharma

In recent years, #drug discovery has undergone a transformative evolution marked by technological advancements and innovative methodologies. This #eBook from Technology Networks explores drug discovery, design and development, highlighting challenges and solutions, successes, various modalities and approaches. https://lnkd.in/eeCMR--U

Thoughts on this? >> New directions in a post IO apocalypse >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #healthcare #competitivemarketing #pharma #biotech

Far too frequently do we see early-stage companies select a preclinical pathway for the wrong drug candidate targeting the wrong indication, inevitably leading to increased costs and delayed program advances, much of which can be avoided with input from an experienced Chief Medical Officer (CMO) executive. To that end I wanted to reach out to highlight our creation of the BJC Capital Advisors’ CMO executive network and underscore the benefit, especially for companies in preclinical development, of accessing an experienced CMO talent to align preclinical programs with your anticipated clinical development strategy.  We encourage you to learn more here - bit.ly/3S5QXh9

The Digital Therapeutics Alliance (DTA) has addressed the cessation of Better Therapeutics' operations and its delisting from Nasdaq, marking a significant moment in the digital health industry. Jessica Hauflaire, DTA's Chief Operating Officer, highlighted the volatile nature of the healthcare innovation sector, acknowledging the challenges that companies like Better Therapeutics face, including regulatory, funding, market adoption, and clinical validation hurdles. Despite this setback, the DTA remains optimistic about the future of #digitalhealth, underscoring its potential to revolutionize patient care, outcomes, and healthcare efficiency through technology, data analytics, and AI. The Alliance calls for continued gratitude, determination, and optimism in advancing digital therapeutics, underscoring the collective effort required to overcome challenges and fully harness the transformative power of digital health (https://lnkd.in/e2gvWuch). The #bankruptcy of Better Therapeutics, following those of Pear Therapeutics and Dthera Sciences, brings to light the precarious yet potentially valuable position of DTx startups within the healthcare innovation landscape. The bankruptcy auction of Pear Therapeutics' assets, which concluded with a $6.05 million sale distributed among Click Therapeutics, Harvest BIO, Nox Health Group, and Welt, vividly illustrates the significant value placed on #intellectualproperty (IP), especially #patents within the DTx sector. Similarly, the acquisition of all Dthera Sciences' patents related to DTx for #Alzheimer’s disease by Telememory Holding Corp further emphasizes this point. These developments raise questions about the future of Better Therapeutics' patents, particularly those concerning DTx for #obesity and type 2 #diabetes, underscoring the critical role of IP in sustaining #innovation and competition in the digital health arena. The strategic acquisitions of Pear's and Dthera's IP assets reflect a broader trend within the DTx field, where patents are increasingly recognized not merely as legal protections but as key assets that drive innovation, expand therapeutic portfolios, and solidify a company's competitive edge in the burgeoning digital health market.

DPHARM: Disruptive Innovations to Advance Clinical Trials is one week away! Will we see you there? As we ramp up to this year's event, we wanted to reflect on the amazing experience we had last year, and all the progress we've made since. Del Smith, PhD and Tiffany Whitlow were honored to win the DPHARM Idol Disrupt award last year, as innovators in the clinical trials space 🎉 Check out the recap of last year's award below, and stay tuned for more updates on what to expect from us at this year's conference! #clinicaltrials #pharma #DEI #pharmaceuticalindustry

Learn about ADME considerations from candidate selection through preclinical and clinical development in our upcoming webinar. Secure your spot now! https://okt.to/4ZGQdo